TY - JOUR
T1 - Emerging Promise of Therapeutic Approaches Targeting Mitochondria in Neurodegenerative Disorders
AU - Rahman, Md Mominur
AU - Tumpa, Mst Afroza Alam
AU - Rahaman, Md Saidur
AU - Islam, Fahadul
AU - Sutradhar, Popy Rani
AU - Ahmed, Muniruddin
AU - Alghamdi, Badrah S.
AU - Hafeez, Abdul
AU - Alexiou, Athanasios
AU - Perveen, Asma
AU - Ashraf, Ghulam Md
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - Mitochondria are critical for homeostasis and metabolism in all cellular eukaryotes. Brain mitochondria are the primary source of fuel that supports many brain functions, including intracellular energy supply, cellular calcium regulation, regulation of limited cellular oxidative capacity, and control of cell death. Much evidence suggests that mitochondria play a central role in neurodegenerative disorders (NDDs) such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and amyo-trophic lateral sclerosis. Ongoing studies of NDDs have revealed that mitochondrial pathology is mainly found in inherited or irregular NDDs and is thought to be associated with the pathophysiological cycle of these disorders. Typical mitochondrial disturbances in NDDs include increased free radical production, decreased ATP synthesis, alterations in mitochondrial permeability, and mitochondrial DNA damage. The main objective of this review is to highlight the basic mitochondrial problems that occur in NDDs and discuss the use mitochondrial drugs, especially mitochondrial antioxidants, mito-chondrial permeability transition blockade, and mitochondrial gene therapy, for the treatment and control of NDDs.
AB - Mitochondria are critical for homeostasis and metabolism in all cellular eukaryotes. Brain mitochondria are the primary source of fuel that supports many brain functions, including intracellular energy supply, cellular calcium regulation, regulation of limited cellular oxidative capacity, and control of cell death. Much evidence suggests that mitochondria play a central role in neurodegenerative disorders (NDDs) such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and amyo-trophic lateral sclerosis. Ongoing studies of NDDs have revealed that mitochondrial pathology is mainly found in inherited or irregular NDDs and is thought to be associated with the pathophysiological cycle of these disorders. Typical mitochondrial disturbances in NDDs include increased free radical production, decreased ATP synthesis, alterations in mitochondrial permeability, and mitochondrial DNA damage. The main objective of this review is to highlight the basic mitochondrial problems that occur in NDDs and discuss the use mitochondrial drugs, especially mitochondrial antioxidants, mito-chondrial permeability transition blockade, and mitochondrial gene therapy, for the treatment and control of NDDs.
KW - Alzheimer’s disease
KW - antioxidants
KW - gene therapy
KW - Mitochondria
KW - neurodegenerative disorders
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=85159633858&partnerID=8YFLogxK
U2 - 10.2174/1570159X21666230316150559
DO - 10.2174/1570159X21666230316150559
M3 - Review article
C2 - 36927428
AN - SCOPUS:85159633858
SN - 1570-159X
VL - 21
SP - 1081
EP - 1099
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 5
ER -